Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu-Long Xie

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Cell Reports. Medicine|October 16, 2024
A phase 2 trial of gemcitabine plus toripalimab for cisplatin-ineligible patients with recurrent or metastatic nasopharyngeal carcinomaXiong Zou, Xi Ding, Zheng-Kai Feng, et al.
Cell Reports. Medicine|November 11, 2023
Efficacy of sequential chemoradiotherapy combined with toripalimab in de novo metastatic nasopharyngeal carcinoma: A phase II trialSi-Yuan Chen, Xiao-Tong Duan, Hui-Feng Li, et al.
European Journal of Cancer (Oxford, England : 1990)|August 20, 2019
Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trialQi Yang, Su-Mei Cao, Ling Guo, et al.
NEJM Evidence|April 22, 2025
Induction versus Concurrent Chemotherapy for Advanced Nasopharyngeal CarcinomaPei-Yu Huang, Xu-Yin Chen, Xi Ding, et al.
JAMA Oncology|July 24, 2020
Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical TrialRui You, You-Ping Liu, Pei-Yu Huang, et al.
Nature Communications|February 5, 2023
Evolutionary route of nasopharyngeal carcinoma metastasis and its clinical significanceMei Lin, Xiao-Long Zhang, Rui You, et al.
Cancer Research|September 6, 2019
Clonal Mutations Activate the NF-κB Pathway to Promote Recurrence of Nasopharyngeal CarcinomaRui You, You-Ping Liu, De-Chen Lin, et al.
Lancet (London, England)|February 26, 2023
Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trialRui You, You-Ping Liu, Yu-Long Xie, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Cell Reports. Medicine|October 16, 2024
A phase 2 trial of gemcitabine plus toripalimab for cisplatin-ineligible patients with recurrent or metastatic nasopharyngeal carcinomaXiong Zou, Xi Ding, Zheng-Kai Feng, et al.
Cell Reports. Medicine|November 11, 2023
Efficacy of sequential chemoradiotherapy combined with toripalimab in de novo metastatic nasopharyngeal carcinoma: A phase II trialSi-Yuan Chen, Xiao-Tong Duan, Hui-Feng Li, et al.
European Journal of Cancer (Oxford, England : 1990)|August 20, 2019
Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trialQi Yang, Su-Mei Cao, Ling Guo, et al.
NEJM Evidence|April 22, 2025
Induction versus Concurrent Chemotherapy for Advanced Nasopharyngeal CarcinomaPei-Yu Huang, Xu-Yin Chen, Xi Ding, et al.
JAMA Oncology|July 24, 2020
Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical TrialRui You, You-Ping Liu, Pei-Yu Huang, et al.
Nature Communications|February 5, 2023
Evolutionary route of nasopharyngeal carcinoma metastasis and its clinical significanceMei Lin, Xiao-Long Zhang, Rui You, et al.
Cancer Research|September 6, 2019
Clonal Mutations Activate the NF-κB Pathway to Promote Recurrence of Nasopharyngeal CarcinomaRui You, You-Ping Liu, De-Chen Lin, et al.
Lancet (London, England)|February 26, 2023
Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trialRui You, You-Ping Liu, Yu-Long Xie, et al.
Pageof 4